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This protocol describes the comparative proteomic profiling of the spleen of wild
type versus mdx-4cv mouse, a model of dystrophinopathy. We detail sample
preparation for bottom-up proteomic mass spectrometry experiments, including
homogenization of tissue, protein concentration measurements, protein diges-
tion, and removal of interfering chemicals. We then describe the steps for mass
spectrometric analysis and bioinformatic evaluation.
For complete details on the use and execution of this protocol, please refer to
Dowling et al. (2020).BEFORE YOU BEGIN
Prior to designing a specific proteomic workflow, it is crucial to initially investigate which biochemical
screening approaches and protein identification methodologies are the most suitable way for the
efficient analysis of the particular type of cell, tissue, or organ under investigation (Kang et al.,
2020). In analytical protein biochemistry, the main high-throughput approaches can be divided
into top-down proteomics versus bottom-up proteomics (Dupree et al., 2020). Besides antibody-
based screening methods, the most frequently employed detection method for protein identifica-
tion is mass spectrometry. Top-down proteomics focuses on the mass spectrometric analysis of
intact proteoforms and is therefore the method of choice for investigating purified protein species
and their post-translational modifications (Dowling et al., 2019). In contrast, bottom-up proteomics
is a peptide-centric technique and highly useful for large-scale studies of protein abundance where
peptides are produced and then analyzed by liquid chromatography-mass spectrometry (Manes and
Nita-Lazar, 2018). Current techniques are highly efficient and allow for the rapid analysis of many
sample types. This protocol represents a typical bottom-up proteomic workflow and was used in
a recent publication (Dowling et al., 2020) to identify proteome-wide changes in the spleen of the
dystrophic mdx-4cv mouse model of Duchenne muscular dystrophy. In Figure 1, the dissection of
mouse spleen is shown. Ideally freshly dissected organs should be used for the initial preparatory
step of comparative proteomic studies.Suitability of Animal Models and Tissue Specimens
Animals should be housed in a clean environment in a certified bioresource facility and kept under
standard conditions (living space, light-dark cycles, nutrient availability). All procedures shouldSTAR Protocols 1, 100196, December 18, 2020 ª 2020 The Author(s).
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Overview of Dissection of Mouse Spleen
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OPEN ACCESS Protocoladhere to local legislation on the use of animals in experimental research. For the comparative
proteomic analysis of the spleen, freshly dissected organs from age- and gender-matched wild
type C57/BL6 mice and dystrophic mdx-4cv mice should be quick-frozen in liquid nitrogen. For
studying the effects of muscular dystrophy, mdx-4cv mice ranging in age from 1 to 12 months
are suitable. Frozen tissue specimens can be transported on dry ice and be stored at 80C for
12 months prior to biochemical analyses. In order to use the most suitable animal model and tis-
sue specimens for studying specific pathophysiological aspects of a human disease by mass spec-
trometry-based proteomics, it is crucial to choose an appropriate genotype, phenotype, and tis-
sue type for sample preparations. In the case of Duchenne muscular dystrophy, the most
frequently inherited neuromuscular disorder of early childhood (Waldrop and Flanigan, 2019),
the mdx-4cv mouse presents an excellent animal model that was generated by chemical mutagen-
esis (Chapman et al., 1989). This dystrophic mouse model of dystrophinopathy exhibits character-
istic pathological hallmarks of skeletal muscle wasting throughout its lifetime, which includes my-
ofiber degeneration, fat substitution, reactive myofibrosis, and sterile inflammation (Murphy et al.,
2019). Progressive dysfunction has also been observed in a variety of other organs, such as the
heart, brain, kidney, and liver (Murphy et al., 2018). The protocol described here using bottom-
up proteomics to study detailed changes in a specific organ, i.e., the mass spectrometric analysis
of the spleen from the mdx-4cv mouse (Dowling et al., 2020), has elucidated the importance of
organ crosstalk in X-linked muscular dystrophy. This pathophysiological complexity of body-
wide alterations makes the mdx-4cv mutant an appropriate mouse model to investigate prote-
ome-wide changes in dystrophinopathy.Choice of Mass Spectrometric Approach
Based on extraordinary advancements in biochemical separation methods and drastic increases
in the detection sensitivity of mass spectrometers, proteomics has developed into an2 STAR Protocols 1, 100196, December 18, 2020
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mass spectrometric research strategies in modern protein biochemistry can be divided into tar-
geted proteomics versus discovery proteomics. Targeted proteomics is mostly concerned with
the detection and absolute quantification of selected target peptides and proteins. In contrast,
discovery proteomics focuses on large-scale protein screening and the analysis of protein dy-
namics in complex cellular systems. In this protocol, discovery proteomics was chosen to
analyze differences in the protein expression profile of the mdx-4cv spleen (Dowling et al.,
2020). For comparative analyses, proteomics, in combination with bioinformatics, can be
used to swiftly determine spatial and temporal alterations in protein expression patterns. This
is especially helpful for studying disease mechanisms and the identification of novel biomarker
candidates. High-throughput mass spectrometric surveys of pathological tissue specimens can
supply large datasets of proteome-wide changes due to pathophysiological abnormalities. It
is therefore critical to choose the most suitable mass spectrometric method for the optimum
biochemical analysis of the protein samples under investigation (Aebersold and Mann, 2016).
Mass spectrometry-based proteomics that uses labeled or label-free proteins can be employed
to determine the relative differences in protein abundances when comparing biological samples
under different conditions (Kang et al., 2020). Routinely used labeling techniques include
isotope-coded affinity tags (ICAT), tandem mass tags (TMT), isobaric tags for relative and ab-
solute quantitation (iTRAQ) and stable isotope labeling by amino acids in cell culture (SILAC),
especially useful in the analysis of cell line models (Craft et al., 2013). Limitations of using la-
beling approaches include cost per experiment, challenging sample preparation and, in some
instances, difficulties with the efficiency of protein labeling. However, for certain proteomic an-
alyses, especially the analysis of post-translational modifications, labeling approaches are an
excellent choice. In label-free quantitation, using peak area and/or spectral counting, the vari-
ability that chemical labeling/tagging may introduce is eliminated, the protocol is more cost-
effective and sample preparation in many cases, is more simplified. All considerations associ-
ated with both labeled or label-free approaches need to be taken into account before a spe-
cific strategy is decided on. The field of mass spectrometry is forever pushing the boundaries
with advanced technologies such as targeted labeling including MRM (Percy et al., 2017) and
PRM (Wilson et al, 2019) approaches, targeted label-free SWATH (Muench et al., 2020) tech-
niques and improved data-acquisition. Suitable instrument and experimental designs are avail-
able with discovery free-label BoxCar methodology (Meier et al., 2018). For this protocol, pep-
tide separation and identification were achieved by combining reverse-phased capillary high-
pressure liquid chromatography and the analytical capability of an Orbitrap Fusion Tribrid
mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).Buffer Preparation
Timing: 3–5 h
1. All essential buffers and solutions should be freshly made prior to sample preparation and used
the same day to avoid any potential degradation of key chemicals. Make sure that there is
enough of all solutions that are required for tissue homogenization, assessment of protein con-
centration, protein digestion, removal of interfering chemicals, liquid chromatography, and
mass spectrometry.
2. All solutions should be prepared with analytical grade chemicals that are suitable for LC-MS anal-
ysis and ultrapure water.
3. Buffers for the initial preparation of tissue extracts should be supplemented with a commercially
available protease inhibitor cocktail to avoid the degradation of sensitive proteins.
4. During all analytical steps, protective gloves, laboratory coat, and face mask should be
worn, especially during preparation of sodium dodecyl sulfate and iodoacetamide containing
buffers.STAR Protocols 1, 100196, December 18, 2020 3
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OPEN ACCESS ProtocolKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins
Ammonium bicarbonate Sigma A6141
Sodium dodecyl sulfate Sigma L3771
Tris base Sigma T1503
Dithiothreitol Thermo Fisher Scientific BP172-5
Iodoacetamide Acros Organics 122270050
Trypsin protease, MS grade Thermo Fisher Scientific 90305
Trifluoroacetic acid Sigma T6508
Acetonitrile Sigma 34851
Formic acid Sigma 5330020050
Urea Sigma U0631
LC-MS grade water Sigma 39253
Bovine serum albumin Thermo Fisher Scientific 23208
Critical Commercial Assays
Pierce 660 nm Protein Assay Reagent Thermo Fisher Scientific 1861426
Ionic Detergent Compatibility Reagent for
Pierce 660 nm Protein Assay Reagent
Thermo Fisher Scientific 22663
Halt Protease Inhibitor Cocktail (1003) Thermo Fisher Scientific 78429
Deposited Data
Open Science Foundation OSF osf.io/f85ve
Experimental Models: Organisms/Strains
C57/BL6 mice Jackson Laboratory 000664
B6Ros.Cg-Dmdmdx-4Cv/J mice Jackson Laboratory 002378
Software and Algorithms
Proteome Discoverer 2.2 using Sequest HT Thermo Fisher Scientific OPTON-30945
Progenesis QI for Proteomics Waters Chromatography Ireland Ltd. n/a
Other
Kinematica Polytron PT1200E handheld
homogenizer
Thermo Fisher Scientific 08-451-164
Filter unit Vivacon 500 Sartorius VN0H22
Pierce C18 spin columns Thermo Fisher Scientific 89870
ThermoMixer Eppendorf 5382000031




Vacuum evaporator Genevac DNA-12060-C00
Microplate reader Thermo Fisher Scientific VL0000D0
Reverse-phased capillary high-pressure
liquid chromatography system
Thermo Fisher Scientific UltiMate 3000 HPLC
Orbitrap Fusion Tribrid mass spectrometer Thermo Fisher Scientific IQLAAEGAAPFADBMBCX
Heated electrospray ionization (H-ESI) ion
source
Thermo Fisher Scientific H-ESI probe
4 STAR Protocols 1, 100196, December 18, 2020
ll
OPEN ACCESSProtocolMATERIALS AND EQUIPMENTTris buffer
Reagent Final concentration VolumeDissolve 12.11 g of Tris in distilled water and make up to a total volume of 1,000 mL with distilled
water. Adjust pH to 7.8 with HCl.
Tris buffer 0.1 M Tris, pH 7.8 1,000 mLAmmonium bicarbonate buffer
Reagent Final concentration Volume
Ammonium bicarbonate buffer 50 mM ammonium bicarbonate in 0.1 M Tris
buffer, pH 7.8
500 mLDissolve 1.95 g of ammonium bicarbonate in Tris buffer and make up to a total volume of 500 mL
with Tris buffer.Homogenization buffer
Reagent Final concentration Volume
Homogenization buffer 1% (w/v) sodium dodecyl sulfate, 0.1 M
dithiothreitol in 50 mM ammonium
bicarbonate buffer
100 mLDissolve 1 g of sodium dodecyl sulfate and 1.54 g of dithiothreitol in 50 mM ammonium bicarbonate
buffer and make up to a total volume of 100 mL with 50 mM ammonium bicarbonate buffer, pH 7.8.
CRITICAL: Sodium dodecyl sulfate is an eye, skin, and respiratory irritant. To preventexposure, make sure to wear suitable protective gloves, as well as protective clothing,
eye protection, a mask, and proper face protection during the handling of sodium dodecyl
sulfate in its powder form.Urea buffer
Reagent Final concentration Volume
Urea buffer 8 M urea in 50 mM ammonium bicarbonate 250 mLDissolve 120.12 g of urea in 50 mM ammonium bicarbonate buffer and make up to a total volume of
250 mL with 50 mM ammonium bicarbonate buffer.
bufferIodoacetamide solution
Reagent Final concentration Volume
Iodoacetamide solution 50 mM iodoacetamide in urea buffer 5 mLDissolve 46 mg of iodoacetamide in urea buffer and make up to a total volume of
5 mL with 8 M urea buffer.
CRITICAL: Iodoacetamide is considered hazardous by the Hazard Communication Stan-dard (29 CFR 1910.1200). According to chemical safety data information, iodoacetamide
is classified as acute toxic, irritant, and a health hazard. To prevent exposure, make sure to
wear suitable protective gloves, as well as protective clothing, eye protection, a mask, and
proper face protection.STAR Protocols 1, 100196, December 18, 2020 5
Digestion buffer
Reagent Final concentration Volume
Digestion buffer 50 mM ammonium bicarbonate with trypsin 5 mL
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OPEN ACCESS ProtocolDissolve 20 ng of trypsin (per 1,000 ng of protein) in ammonium bicarbonate buffer andmake up to a
total volume of 5 mL with 50 mM ammonium bicarbonate buffer.
(50:1 protein:trypsin ratio)Sample buffer
Reagent Final concentration Volume
Sample buffer 2% (v/v) trifluoroacetic acid, 20% (v/v)
acetonitrile
20 mLGently mix 0.4 mL of trifluoroacetic acid with 4 mL of acetonitrile and make up to a total volume of
20 mL with LC-MS grade water.Activation solution
Reagent Final concentration Volume
Activation solution 50% (v/v) acetonitrile 20 mLGently mix 10mL of acetonitrile with LC-MS grade water andmake up to a total volume of 20mL with
LC-MS grade water.Equilibration/wash solution
Reagent Final concentration Volume
Equilibration/wash solution 0.5% (v/v) trifluoroacetic acid in 5% (v/v)
acetonitrile
50 mLGently mix 0.25mL of trifluoroacetic acid with 2.5mL of acetonitrile andmake up to a total volume of
50 mL with LC-MS grade water.Elution buffer
Reagent Final concentration Volume
Elution buffer 80% (v/v) acetonitrile 5 mLGently mix 4 mL of acetonitrile with LC-MS grade water and make up to a total volume of 5 mL with
LC-MS grade water.Resuspension buffer
Reagent Final concentration Volume
Resuspension buffer 2% (v/v) acetonitrile, 0.1% (v/v)
trifluoroacetic acid
5 mLGently mix 0.1 mL of acetonitrile with 5 mL of trifluoroacetic acid and make up to a total volume of
5 mL with LC-MS grade water.Trapping buffer
Reagent Final concentration Volume
Trapping buffer 2% (v/v) acetonitrile, 0.1% (v/v)
trifluoroacetic acid
1,000 mL
6 STAR Protocols 1, 100196, December 18, 2020
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1,000 mL with LC-MS grade water.LC – Solvent A
Reagent Final concentration Volume
LC - Solvent A 0.1% (v/v) formic acid in LC-MS grade water 1,000 mLGently mix 1 mL formic acid with LC-MS grade water and make up to a total volume of 1,000 mL with
LC-MS grade water.LC – Solvent B
Reagent Final concentration Volume
LC - Solvent B 80% (v/v) acetonitrile, 0.08% (v/v) formic acid
in LC-MS grade water
1,000 mLGently mix 800 mL of acetonitrile with 0.8 mL of formic acid and make up to a total volume of
1,000 mL with LC-MS grade water.STEP-BY-STEP METHOD DETAILS
Tissue Homogenization
Timing: 2–3 h
Prior to protein extraction for mass spectrometric analysis, a crucial step of comparative proteomic
studies is the reproducible homogenization of the biological material of interest. In the case of small
tissue/organ specimens from mice such as the spleen, a handheld device is in our experience ideal
for swift and efficient tissue homogenization in small sample volumes (Dowling et al., 2020). Various
types of handheld devices are available. In this protocol, the Kinematica Polytron model PT1200E
was used for the efficient homogenization of mouse spleen specimens. During the initial preparation
of tissue extracts, buffers should be supplemented with a suitable protease inhibitor cocktail to
avoid the degradation of potentially sensitive proteins. Treatment at 95C is a suitable approach
to counteract the masking effect that highly abundant proteins such as albumin have with respect
to maximizing the number of proteins identified in biological samples (Chiangjong et al., 2019).
High temperature precipitation of thermolabile proteins is a relatively straightforward step and com-
pares favorably to optimize demanding protocols for high abundant protein removal such as immu-
nodepletion. For mass spectrometric analyses, sufficient biological and technical repeats should be
used for the statistical evaluation of protein hits. Ideally, n=6 biological repeats and n=2 technical
repeats per specimen of interest are employed to account for potential biological and bioanalytical
variations.
1. Homogenize mouse spleen tissue (25 mg wet weight) using a handheld homogenizer in 150 mL of
homogenization buffer, supplemented with 13 protease inhibitor cocktail. The ratio of tissue to
buffer should be 1:6 (mg/mL).
2. Heat the suspension at 95C for 5 min.
3. Sonicate the suspension using 4 bursts of 5 s to shear the DNA to reduce the viscosity of the sam-
ple.
4. Centrifuge the suspension at 20,000 3 g for 10 min to clarify the homogenate.
5. Determine protein concentration using the Pierce 660 nm protein assay kit.Protein Determination
Timing: 1–2 hSTAR Protocols 1, 100196, December 18, 2020 7
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individual samples. This can be conveniently carried out with a variety of commercially available pro-
tein assays. In this protocol, the Pierce 660 nm Protein Assay system (Antharavally et al., 2009) and
pre-prepared protein standards were employed for the swift determination of protein concentra-
tion. Since the protocol described here uses detergents during the homogenization step, ionic
detergent compatibility reagent has to be added to the protein assay reagent.
6. Add 10 mL of each protein standard, such as bovine serum albumin (25, 50, 125, 250, 500, 750,
1,000, 1,500 and 2,000 mg/mL), the unknown samples and the appropriate blank sample (ho-
mogenization buffer) into a microplate well in triplicate.
7. Add 150 mL of the protein assay reagent (supplemented with ionic detergent compatibility re-
agent) to each well.
8. Cover plate and mix on a plate shaker at medium speed (of approximately 600 rpm) for 1 min
and incubate at 20C for 5 min.
9. Use the blank wells to zero the plate reader. Measure the absorbance of the standards and un-
known samples at a wavelength of l = 660 nm.
10. Prepare a standard curve by plotting the average blank-corrected 660 nm measurement for
each bovine serum albumin standard versus its concentration in mg/mL.
11. Use the standard curve to determine the protein concentration of each unknown sample, using a
four-parameter (quadratic) curve fit.
Protein Digestion
Timing: 10–24 h
A key step of bottom-up proteomics is the controlled digestion of protein mixtures with a suitable
protease. The most commonly used protease is trypsin and is also employed in this protocol. Alter-
native digestion strategies can be carried out with the enzyme Lys-C or combinations of Lys-C and
trypsin, as well as a variety of other proteases or chemicals (Murphy and Ohlendieck, 2018). The
workflow of tissue homogenization, protein determination, and protein digestion, as well as the sub-
sequent peptide mass spectrometric analysis, protein identification, and bioinformatic analysis, is
summarized in the flowchart of Figure 2. In this protocol, a filter-aided sample preparation approach,
usually abbreviated as FASP, is used for processing the sodium dodecyl sulfate-solubilized spleen
cells in a centrifugal filter unit (Wisniewski, 2018). The disposable centrifugal ultrafiltration units
can be conveniently used for the sequential removal of excess detergent, the controlled trypsination
of proteins and the subsequent isolation of generated peptide populations. Prior to conducting fil-
ter-aided sample preparations, the appropriate cutoff size of the filter units (e.g., 10,000, 30,000 or
50,000MWCO) should be evaluated for particular samples and types of analyses. For optimum chro-
matographical separation and subsequent mass spectrometric analysis, the choice of molecular
weight cutoff should on the one hand prevent the retention of interfering chemicals and on the other
hand not result in the loss of peptides/proteins. In our experience, the usage of smaller pore size cut-
off filters (10 kDa) results in the retention of chemicals that can alter chromatography. Using a filter
with a 30 kDa pore size reduces this interference greatly resulting in more reproducible data.
12. Combine 25 mg of sample homogenate (maximum volume of 30 mL) with 200 mL urea buffer in
the Sartorius Vivacon 500 centrifugal filter unit.
13. Briefly vortex and centrifuge at 14,000 3 g for 15 min.
14. Add 200 mL of urea buffer to the filter unit, briefly vortex and then centrifuge at 14,0003 g for
15 min. Discard the flow-through solution.
15. Add 100 mL of iodoacetamide solution. This solution is light sensitive. Therefore, the filter
units should be covered in tinfoil.
16. Mix this solution at 600 rpm in a thermomixer for 1min and incubate without mixing for 20min
in the dark.8 STAR Protocols 1, 100196, December 18, 2020
Figure 2. Workflow of the Comparative andMass Spectrometry-Based Proteomic Profiling of the Spleen fromWild
Type versus the Dystrophic mdx-4cv Mouse Model of Duchenne Muscular Dystrophy
The corresponding experimental steps are listed in parentheses.
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OPEN ACCESSProtocol17. Centrifuge at 14,000 3 g for 15 min.
18. Add 100 mL urea buffer to the filter unit.
19. Briefly vortex and centrifuge at 14,000 3 g for 15 min.
20. Repeat this step by adding 100 mL urea buffer, followed by vortexing and centrifugation at
14,000 3 g for 15 min.
21. Add 100 mL of ammonium bicarbonate buffer.
22. Briefly vortex and centrifuge at 14,000 3 g for 15 min.STAR Protocols 1, 100196, December 18, 2020 9
Figure 3. Image of a Pipette Box Containing Water and Soaked Tissue Sheets and Filter Unit Tubes Held in Foam
Floater for Incubation in a Wet Chamber (Step 27)
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centrifugation at 14,000 3 g for 15 min.
24. Transfer the filter units to new collection tubes.
25. Add 40 mL of trypsin-containing digestion buffer and keep this solution on ice.
26. Mix the solution at 600 rpm in a thermomixer for 1 min.
27. Incubate the filter units in a wet chamber. This can be constructed with a pipette box containing
water and soaked tissue sheets and tubes held in foam floater, as illustrated in Figure 3. Incuba-
tion should be carried out in a sterile incubator at 37C for 4–18 h.
28. Place filter units in new collection tubes.
29. Collect the peptide-containing filtrate by centrifugation at 14,000 3 g for 10 min.
30. Add 40 mL of ammonium bicarbonate buffer and re-centrifuge the filter units at 14,000 3 g for
10 min.
31. Add 60 mL of each sample to new Eppendorf tubes and add 15 mL of sample buffer (containing
2% (v/v) trifluoroacetic acid and 20% (v/v) acetonitrile), so that the peptide sample solution con-
tains 0.5% trifluoroacetic acid in 5% acetonitrile.Peptide Clean Up to Remove Interfering Chemicals
Timing: 1–3 h
In order to remove interfering chemicals prior to mass spectrometric analysis, peptide-containing
samples are washed and centrifuged prior to elution and liquid chromatographical separation.
32. Place C18 spin tubes into receiver tubes.
33. Add 200 mL of Activation Solution to rinse walls of the C18 spin tubes and to wet resin.
34. Centrifuge at 1,500 3 g for 1 min and discard flow-through solution.
35. Repeat steps 33 and 34.
36. Add 200 mL Equilibration/Wash Solution.
37. Centrifuge at 1,500 3 g for 1 min and discard flow-through solution.
38. Repeat steps 35 and 36.
39. Pipette sample on top of resin bed.
40. Place C18 spin tubes into receiver tubes.
41. Centrifuge at 1,500 3 g for 1 min.
42. To ensure complete binding, recover flow-through and repeat steps 39–41.
43. Place C18 spin tubes into new receiver tubes.
44. Add 200 mL Equilibration/Wash Solution to C18 spin tube and centrifuge at 1,5003 g for 1 min
and discard flow-through solution.
45. Repeat step 44.10 STAR Protocols 1, 100196, December 18, 2020
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47. Add 20 mL of Elution Buffer to top of the resin bed.
48. Centrifuge at 1,500 3 g for 1 min.
49. Repeat steps 47 and 48 with same receiver tubes.
50. Gently dry sample in a vacuum evaporator and resuspend sample in 50 mL of resuspension
buffer, so that the peptide sample solution contains 2% (v/v) acetonitrile and 0.1% (v/v) trifluoro-
acetic acid.Liquid Chromatography-Mass Spectrometry Using Orbitrap Fusion Tribrid
Timing: 12–72 h (depending on the number of samples to be analyzed by LC-MS)
A key bioanalytical step of bottom-up proteomics is the peptide-centric identification of protein spe-
cies. Peptides generated by trypsin treatment are separated by reverse-phased liquid chromatog-
raphy and then analyzed by mass spectrometry (Sethi et al., 2015). The amino acid sequence infor-
mation of individual peptides is combined and then used for the systematic identification of
individual proteoforms.
51. Using a liquid chromatography system (for example the Thermo Scientific UltiMate
3000 UHPLC), load 2 mL of protein digest onto the trapping column (PepMap100, C18,
300 mm 3 5 mm - Thermo Fisher Scientific) at a flow rate of 25 mL/min with trapping buffer for
3 min before being resolved onto an analytical column (Acclaim PepMap 100, 75 mm 3
50 cm, 3 mm bead diameter column).
52. Elution of peptides is carried out with the following binary gradient; LC Solvent A and LC Solvent
B using 2%–32% Solvent B for 75min, 32%–90% Solvent B for 5 min and holding at 90% for 5min
at a flow rate of 300 nL/min.
53. For peptide identification analysis, a data-dependent acquisition method is selected using a
voltage of 2.0 kV and a capillary temperature of 320C.
54. Data-dependent acquisition with full scans in the 380–1,500 m/z range is performed using an
mass analyzer (for example the Thermo Scientific Orbitrap Fusion Tribrid) with a resolution of
120,000 (at m/z 200), a targeted automatic gain control (AGC) value of 4E+05 and a maximum
injection time of 50 ms.
55. The number of selected precursor ions for fragmentation is determined by the top-speed acqui-
sition algorithm.
56. Selected precursor ions are isolated in the Quadrupole with an isolation width of 1.6 Da.
57. Peptides with a charge state of 2+ to 7+ are analyzed and a dynamic exclusion is applied after
60 s.
58. Precursor ions are fragmented using higher energy collision-induced dissociation with a normal-
ized collision energy of 28%. Resulting MS/MS ions are measured in the linear ion trap.
59. The typical MS/MS scan conditions are as follows: a targeted AGC value of 2E+04 and a
maximum fill time of 35 ms.Peptide and Protein Identification
Timing: 2–3 h
In order to analyze mass spectrometric files, commercially available software programs can be used.
It is crucial to define suitable search parameters for proper protein identification.
60. For data analysis of mouse proteins, mass spectrometric files (.raw) are searched against the Uni-
ProtKB-SwissProt Mus musculus database with Proteome Discoverer 2.2 using Sequest HT and
Percolator.STAR Protocols 1, 100196, December 18, 2020 11
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Mus musculus for Mouse) at https://www.uniprot.org/proteomes/.
62. Click on the Proteome ID link - UP000000589.
63. UniProt offers different databases to select from, including reviewed (UniProtKB/Swissprot), un-
reviewed (UniProtKB/TREMBL) or both (UniProtKB) options. In model organisms such as mice,
which are researched extensively, reviewed (Swissprot) databases contain highly curated (i.e.,
carefully annotated) entries, a minimal level of redundancy and the ability to integrate with other
databases efficiently.
64. Click on the Download button and choose: All protein entries, Fasta (Canonical and isoform),
compressed.
65. The following search parameters are a useful guide for protein identification:
a. Peptide mass tolerance set to 10 ppm.
b. MS/MS mass tolerance set to 0.6 Da.
c. Up to two missed peptide cleavages should be allowed.
d. Carbamidomethylation of cysteine set as a fixed modification.
e. Methionine oxidation set as a variable modification.
66. Importantly, only highly confident peptide identifications with a false discovery rate (FDR) %
0.01, identified using a SEQUEST HT workflow coupled with Percolator validation in Proteome
Discoverer 2.2, should be considered.
Comparative Protein Abundance Profiling Using Progenesis QI Analysis
Timing: 6–48 h
The comparative proteomic analysis of different protein populations can be carried out by commer-
cially available software programs. For example, protein extracts of tissue preparations from wild
type versus mutant specimens can lead to the identification of hundreds of differentially expressed
protein species. This protocol is based on the recent proteomic profiling of the spleen from normal
versus dystrophic mdx-4cv mice (Dowling et al., 2020).
67. Using Progenesis QI (Waters) for comparative abundance profiling, mass spectrometric raw
files are imported into the software and automatic run alignment can be used to combine and
compare the result from different LC-MS runs.
68. Automatic peak picking and matching across all data files is carried out to create an aggre-
gate dataset from the aligned runs. For a representative example, see Figure 4.
69. This contains all peak information from all sample files used and allows the detection of a sin-
gle map of peptides.
70. Thismap is then applied to each sample, giving 100%matchingof peakswith nomissing values.
71. The peptide ion abundance measurements are normalized allowing for the comparisons be-
tween the wild type and the mutant specimens in order to identify peptides of biological in-
terest. For a representative example, see Figure 5.
72. The peptide ions of interest are determined based on the significance measure of ANOVA
with a p-value of 0.05.
73. MS/MS spectra from these peptides are exported and identified using the process above
using Proteome Discoverer 2.2 software. For user guides and tutorial datasets of Progenesis
QI for proteomics, see: http://www.nonlinear.com/progenesis/qi-for-proteomics/v4.0/
user-guide/).
74. The result file is re-imported in Progenesis QI which allows a review of all the peptide ions
used to quantify and identify individual protein species.
75. The proteins of interest are then determined based on the significance measure of ANOVA
with a p-value of 0.05.
76. It is crucial to review quality control metrics before finalizing the list of significant proteins with a
changed abundance. Critical metrics to be considered include:12 STAR Protocols 1, 100196, December 18, 2020
Figure 4. Aggregate Dataset from Aligned Runs
Shown is a representative example of a reference run that other samples are aligned to (step 68).
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OPEN ACCESSProtocola. Sample preparation metrics – highlighting issues or problems with the preparation of your sam-ples, for example problems due to missed peptide cleavages.b. Instrument metrics – highlighting whether your chromatography column and mass spectrom-eter are configured and performing correctly, for example issues with column deterioration.c. Experiment metrics – concerning the identified proteins and peptides in your experiment, forexample the identification of statistical outliers in the sample set.Systems Bioinformatics
Timing: days to weeks
For further analyses of proteomic datasets and sequence information of individual proteoforms of
biological or pathophysiological interest, a large variety of publicly accessable bioinformatics pro-
grams are available. Bioinformatics can be used to model protein structures, determine the distribu-
tion of distinct protein families within large proteomic datasets, evaluate the affiliation of individual
proteins to biochemical pathways or protein assemblies, and establish potential protein-protein
interaction patterns between identified proteoforms (Na and Paek, 2020). Below listed are
commonly employed search programs for the systematic analysis of proteomic data.
77. Proteomic datasets and peptide sequences can be further analyzed by a variety of bioinformatic
software programs, such as:
a. UniProt (https://www.uniprot.org): Comprehensive database of protein sequence and func-tional information.b. BLAST (https://blast.ncbi.nlm.nih.gov): BLASTP is an algorithm and search program forcomparing amino acid sequences of proteins.c. PANTHER (http://www.pantherdb.org): The PANTHER classification system is a large curatedbiological database of gene/protein families and their functionally related subfamilies
that can be used to classify and identify the function of gene products.d. STRING (https://string-db.org): Program for the identification of protein-protein interactionnetworks and functional enrichment analysis.STAR Protocols 1, 100196, December 18, 2020 13
Figure 5. Comparisons between Wild Type and Mutant Specimens in Order to Identify Peptides of Biological
Interest
Shown is a representative example of clustering (wt samples marked in purple vs mdx-4cv samples marked in orange)
based on significant peptides (step 71).
ll
OPEN ACCESS Protocole. REACTOME (www.reactome.org): Database that provides a bioinformatics tools for the visual-14ization and analysis of biological pathways.f. piNET (www.pinet-server.org): Server for peptide-centric post-translational modification map-ping, differential expression analysis, gene (protein) enrichment analysis, and Library of In-
tegrated Network-based Cellular Signatures (LINCS) connectivity mapping.g. DAVID (https://david.ncifcrf.gov): Database for annotation, visualization, and integrated dis-covery that provides a comprehensive set of functional annotation tools for studying the
biological meaning of large lists of genes.h. KEGG (https://www.genome.jp/kegg/): Database resource for studying high-level functionsand utilities of biological systems using large-scale molecular datasets.i. Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2): Automatic fold recognition server for predicting
the structure of peptide and protein sequences.Verification Analysis
Timing: weeks to months
Mass spectrometry-based proteomics is an unbiased and technology-driven approach in explor-
atory bioresearch. Thus, the design of a comparative proteomic study is not necessarily based on
a specific biological hypothesis, but is instead valuable in formulating novel research questions. Pro-
teomic findings can therefore form the rationale for new bioanalytical avenues in a specific area of
research. This frequently includes crucial and independent verification experiments to confirm pro-
teomic findings (Dowling et al., 2020). Below listed are a few of the most commonly performed ex-
periments to further investigate the biological or pathophysiological meaning of findings from pro-
teomic surveys.
78. To confirm and interpret proteomic hits or data from comparative mass spectrometric studies, a
large variety of standard biochemical and cell biological techniques are used, including:a. ImmunoblottingSTAR Protocols 1, 100196, December 18, 2020
ll
OPEN ACCESSProtocolb. Enzyme assays
c. Protein binding assays
d. Immunofluorescence microscopy
e. Physiological assaysEXPECTED OUTCOMES
Proteomics has developed into a key biochemical methodology for the systematic cataloging of pro-
tein populations in biofluids, cells, tissues, and organs (Uzozie and Aebersold, 2018), whereby the
development of highly sensitive mass spectrometric methods plays a central role in the unequivocal
identification of individual proteoforms (Kang et al., 2020). This protocol describes a typical bottom-
up proteomic approach (Dupree et al., 2020) that has combined tissue homogenization, protein con-
centration measurements, controlled protein digestion by trypsination, the removal of interfering
chemicals, peptide sequencing with the help of an Orbitrap Fusion Tribrid mass spectrometer
and bioinformatic analysis of proteomic data (Dowling et al., 2020). The expected outcome of a
typical proteomic survey of crude tissue samples is the identification of several thousand individual
proteins. For example, the recent proteomic cataloging of 12-month old mouse spleen resulted in
the identification of 5,688 splenic protein species (Dowling et al., 2020). Importantly, the protocol
described here for the bottom-up proteomic analysis of mouse spleen has identified a large number
of splenic marker proteins. Figure 6 shows a representative finding and illustrates the proteomic re-
sults for the CD5 antigen-like protein. This protein, which was previously shown to be one of the
most highly expressed splenic proteins (Uhlén et al., 2015), was identified by 14 unique peptides
with a 47% coverage of the total protein sequence. The CD5L protein is mainly expressed by mac-
rophages in lymphoid tissues and regulates mechanisms in inflammatory responses (Sanjurjo et al.,
2015). Table 1 is an example of how proteomic surveys of specific tissues and organs can be em-
ployed to define the expression levels of a distinct family of proteins. The table lists the heat shock
protein class of molecular chaperones (Saibil, 2013) that were identified by the described protocol
for the proteomic profiling of mouse spleen. The 15 splenic heat shock proteins range in molecular
mass from 11 to 96 kDa and include several sub-classes of molecular chaperones, such as small heat
shock proteins (HspB, HspE), medium size heat shock proteins (HspA, HspD) and large heat shock
proteins (Hsp90, HspH). These findings demonstrate the comprehensive coverage and detection
sensitivity of the protocol outlined here for the proteomic profiling of spleen tissue (Dowling
et al., 2020).LIMITATIONS
Although mass spectrometry-based proteomics is an excellent method for the comprehensive cata-
loging of large and complex mixtures of proteins from biological specimens, a given proteomic pro-
file represents nevertheless only a snapshot of protein expression at a specific point in time. In
contrast to the highly stable genome, the proteome of a specific cell is a highly dynamic entity
that permanently adapts to changing physiological demands, metabolic alterations, and biochem-
ical challenges (Walther and Mann, 2010). This limits the potential of interpreting proteomic results
from a single analysis in relation to temporal changes in a biological system. Thus, studying the time
course of proteome-wide alterations requires the mass spectrometric analysis of many time points,
which can be both prohibitively costly and very laborious. Comparative proteomic surveys can be
used to determine large-scale changes due to pathological mechanisms. This can be helpful to un-
derstand specific aspects of the molecular and cellular pathogenesis of a particular disorder, as well
as for testing new therapeutic strategies and the identification of novel biomarker candidates (Dow-
ling et al., 2016). However, as already described above, the observed changes in protein expression
patterns neither give detailed information on the exact time course of pathobiochemical alterations
nor provide a detailed mechanistic understanding of disease progression. Another potential limita-
tion of the described protocol is a general issue with the usage of animal models in biomedical
research. In genetic disorders, a comparable genotype might not be reflected by all pathophysio-
logical aspects in the phenotype (Wilson et al., 2017). For example, the mdx-type mouse modelsSTAR Protocols 1, 100196, December 18, 2020 15
Figure 6. Proteomic Identification of the Splenic CD5 Antigen-like Protein in Mouse Spleen
The upper panel gives an overview of the proteomic strategy used in this protocol to identify individual proteoforms in
the spleen. The lower panel shows the mass spectrometric coverage of the amino acid sequence of the CD5 antigen-
like protein. Unique peptides determined by LC-MS/MS analysis are marked in red and bold letters. The protein
sequence was used for the molecular modeling of the splenic isoform of the CD5L protein with the help of the publicly
available software program Phyre2 for protein structure prediction. The molecular model highlights the predicted
positions of a helixes, b sheets, and connecting loops within the tertiary structure of the splenic CD5L protein
(accession number UniProt: Q9QWK4) of apparent 38.8 kDa.
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OPEN ACCESS Protocolof Duchenne muscular dystrophy, which have been utilized in this protocol, exhibit a milder pattern
of fiber degeneration in most limb and trunk muscles as compared to patients suffering from dystro-
phinopathy (Doran et al., 2007). It is therefore important to interpret the proteomic data generated
with the help of animal models with caution. Ideally, verification experiments are extended to the
screening of patient biopsy material.
TROUBLESHOOTING
Problem 1
Difficulty with small sample size of tissues from mouse models (step 1).
Potential Solution
For the reproducible extraction of representative protein preparations from a specific type of mouse
cell, tissue, or organ, it is crucial to use large enough starting material (25 mg wet weight). If only
small quantities of biological specimens can be extracted from a single individual, then samples
can be pooled from several animals. Alternatively, older animals with larger organs can be utilized
if the age range is suitable for the particular biomedical analysis.
Problem 2
Interference of chemicals such as detergent in protein assays (step 7).
Potential Solution
Various commonly used biochemicals may interfere with protein assays. In the case of detergents,
which are used in this protocol during the homogenization in buffer that contains 1% (w/v) sodium
dodecyl sulfate, the protein assay reagent should be supplemented with an ionic detergent compat-
ibility reagent. For the Pierce 660 nm Protein Assay system, such a compatibility reagent is commer-
cially available and can be conveniently added to the detection solution prior to protein
measurements.16 STAR Protocols 1, 100196, December 18, 2020











Q61699 Heat shock protein 105 kDa Hsph1 39 26 24 96.3
P07901 Heat shock protein HSP 90-alpha Hsp90aa1 54 43 27 84.7
P11499 Heat shock protein HSP 90-beta Hsp90ab1 58 50 32 83.2
Q9CQN1 Heat shock protein 75 kDa,
mitochondrial
Trap1 41 22 21 80.2
P17879 Heat shock 70 kDa protein 1B Hspa1b 37 19 13 70.1
Q61316 Heat shock 70 kDa protein 4 Hspa4 56 39 36 94.1
P48722 Heat shock 70 kDa protein 4L Hspa4l 27 17 15 94.3
P63017 Heat shock cognate 71 kDa protein Hspa8 64 38 26 70.8
Q8K0U4 Heat shock 70 kDa protein 12A Hspa12a 6 3 3 74.8
Q8BM72 Heat shock 70 kDa protein 13 Hspa13 3 1 1 51.7
Q99M31 Heat shock 70 kDa protein 14 Hspa14 24 8 8 54.6
P17156 Heat shock-related 70 kDa
protein 2
Hspa2 26 16 4 69.6
P63038 60 kDa heat shock protein,
mitochondrial
Hspd1 62 31 31 60.9
P14602 Heat shock protein beta-1 Hspb1 54 9 9 23.0
Q64433 10 kDa heat shock protein,
mitochondrial
Hspe1 60 6 6 11.0
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OPEN ACCESSProtocolProblem 3
Mass spectrometric profiling results in an exceedingly long list of poor proteomic hits (step 65).
Potential Solution
During data analysis, it is crucial to define strict search parameters for the establishment of a useful
list of identified protein species. Critical parameters include peptide mass tolerance, MS/MS mass
tolerance and the number of missed peptide cleavages, as well as settings for certain chemical mod-
ifications such as carbamidomethylation of cysteine residues and methionine oxidation. For the un-
equivocal identification of individual proteoforms, another set of parameters can be concerned with
the minimum number of unique peptides and the percent coverage of the total protein sequence.
Problem 4
Low number of identified proteins with a differential expression pattern in pathological specimens
(step 76).
Potential Solution
The number of significant protein hits following the comparative proteomic analysis of normal con-
trols versus disease samples depends heavily on the severity of the pathological phenotype. While
mild pathologies might result only in a few changed proteins, severe degenerative processes can
trigger alterations in the expression patterns of hundreds of proteins. Thus, if only relatively few pro-
teins are identified that exhibit a differential expression pattern in mutant specimens from an animal
model of a human disease, this can be due to a mild phenotype or an unsuitable genetic model sys-
tem. In the latter case, it is advisable to try other animal models that might better mimic specific as-
pects of the human pathology.
Problem 5
Poor data alignment in Progenesis QI for proteomics (step 67).STAR Protocols 1, 100196, December 18, 2020 17
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OPEN ACCESS ProtocolPotential Solution
If the automatic alignment process fails to align your runs acceptably during the first round of anal-
ysis, manual alignment vectors can be included before automatic alignment is started for a second




Further information and requests for resources and reagents should be directed to and will be ful-
filled by the Lead Contact, Kay Ohlendieck (kay.ohlendieck@mu.ie).
MATERIALS AVAILABILITY
This study did not generate new unique reagents.
Data and Code Availability
This protocol has been used to generate proteomic datasets from mouse spleen. The mass spectro-
metric analysis of 14 separate sample runs have been deposited to the Open Science Framework
repository as OSF entry ‘‘f85ve’’ under the following link: https://osf.io/f85ve/. This link also features
a multi-consensus file of the proteomic cataloging of mouse spleen with the help of an Orbitrap
Fusion Tribrid mass spectrometer.
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